COST-EFFECTIVENESS ANALYSIS OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR VERSUS CLOPIDOGREL IN HONG KONG: A MARKOV ANALYTIC MODEL

被引：0
|
作者：
Lee, V. W. Y. [1 ]
Chow, I. H. I. [1 ]
Yan, B. P. [2 ,3 ]
Yu, C. M. [1 ]
Lam, Y. Y. [1 ]
机构：
[1] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[2] Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Monash Univ, Hong Kong, Hong Kong, Peoples R China
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.993
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A371 / A371
页数：1
相关论文
共 50 条
  • [41] COST-EFECTIVENESS OF GENOTYPE/PHENOTYPE DRIVEN TICAGRELOR VERSUS CLOPIDOGREL SELECTION IN THE PATIENTS WITH ACUTE CORONARY SYNDROME
    Kim, Kibum
    Ardati, Amer
    DiDomenico, Robert
    Cavallari, Larisa
    Touchette, Daniel R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A24 - A24
  • [42] A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China
    Ming Cui
    Chen Chen Tu
    Er Zhen Chen
    Xiao Li Wang
    Seng Chuen Tan
    Can Chen
    Advances in Therapy, 2016, 33 : 1600 - 1611
  • [43] A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China
    Cui, Ming
    Tu, Chen Chen
    Chen, Er Zhen
    Wang, Xiao Li
    Tan, Seng Chuen
    Chen, Can
    ADVANCES IN THERAPY, 2016, 33 (09) : 1600 - 1611
  • [44] Effectiveness and Safety of Ticagrelor versus Clopidogrel in Acute Coronary Syndrome: A Meta-Analysis of Real - World Data
    Al-Balushi, Sara
    Rahhal, Alaa
    Abdelghani, Mohamed
    Ashour, Mohammed Awad
    Al-Mohtasib, Yazan
    Abid, Abdul R.
    Alsuwaidi, Jassim
    CIRCULATION, 2022, 146
  • [45] Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention
    Li, Yuzhuo
    Li, Jing
    Qiu, Miaohan
    Ma, Sicong
    Na, Kun
    Li, Xiaoying
    Qi, Zizhao
    Chen, Sanbao
    Li, Yi
    Han, Yaling
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2022, 99 : 1395 - 1402
  • [46] A Cost-Effectiveness Analysis of "Test'' versus "Treat'' Patients Hospitalized with Suspected Influenza in Hong Kong
    You, Joyce H. S.
    Chan, Eva S. K.
    Leung, Maggie Y. K.
    Ip, Margaret
    Lee, Nelson L. S.
    PLOS ONE, 2012, 7 (03):
  • [47] Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis
    Crespin, Daniel J.
    Federspiel, Jerome J.
    Biddle, Andrea K.
    Jonas, Daniel E.
    Rossi, Joseph S.
    VALUE IN HEALTH, 2011, 14 (04) : 483 - 491
  • [48] Cost-Effectiveness of 12-Month Treatment With Ticagrelor Compared With Clopidogrel in the Management of Acute Coronary Syndromes
    Liew, Danny
    Lourenco, Richard De Abreu
    Adena, Michael
    Chim, Lesley
    Aylward, Philip
    CLINICAL THERAPEUTICS, 2013, 35 (08) : 1110 - 1117
  • [49] Evaluation of the cost-effectiveness of an integral model of ambulatory treatment in patients with acute coronary syndrome: application of a probabilistic Markov model
    Salgado, Kelly
    Carlos Salazar-Uribe, Juan
    Gallo-Villegas, Jaime
    Valencia, Angela
    Espindola-Fernandez, Diego
    Mesa, Cristina
    de la Calle, Juan
    Montoya, Yanett
    Aristizabal, Dagnovar
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2018, 42
  • [50] Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
    He, Peixun
    Luo, Xiaolin
    Li, Jiabei
    Li, Yi
    Wang, Xiaozeng
    Huang, Lan
    Jin, Jun
    Han, Yaling
    CARDIOVASCULAR THERAPEUTICS, 2021, 2021
12345